
Ozempic vs Mounjaro: What The New Heart-Risk Study Really Found
A huge new real-world study has added another twist to the Ozempic-versus-Mounjaro debate. Researchers examined healthcare data from more than 636,000 adults with type 2 diabetes and found that patients who increased semaglutide from 1 mg to 2 mg had a statistically significant 6 per cent lower risk of major cardiovascular events than those who switched to tirzepatide.
But that headline needs context. This was not a randomised head-to-head cardiovascular trial, and other recent studies comparing semaglutide with tirzepatide have reached different conclusions.
This episode explains what…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.